Tacrolimus therapy for ABO-incompatible kidney transplantation.
Takahashi
K
K
Department of Urology, Niigata University School of Medicine, Japan.
Saito
K
K
Sonda
K
K
Nakagawa
Y
Y
Katagiri
A
A
Tomita
Y
Y
Tanigawa
T
T
Takeda
M
M
D000017:ABO Blood-Group System; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001787:Blood Group Incompatibility; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D006085:Graft Survival / Q000187:drug effects*; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*
D000017:ABO Blood-Group System; D000961:Antilymphocyte Serum; D006146:Guanidines; D007166:Immunosuppressive Agents; D001379:Azathioprine; C037258:gusperimus; D016559:Tacrolimus; D008775:Methylprednisolone